2018年8月
High-dose chemotherapy with autologous stem cell transplantation spares re-irradiation for recurrent intracranial germinoma.
Pediatric blood & cancer
- 巻
- 65
- 号
- 8
- 開始ページ
- e27104
- 終了ページ
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1002/pbc.27104
The clinical outcome of high-dose chemotherapy (HDC) with autologous stem cell transplantation was retrospectively analyzed in six patients with recurrent intracranial germinoma. Prior to HDC, all patients achieved complete remission after platinum and ifosfamide-based chemotherapy. A melphalan-based conditioning regimen was administered in either a single cycle or multiple sequential cycles. Five of the six patients are alive and free from disease, with a median survival of 65 months, among which four patients avoided re-irradiation. In a significant proportion of patients, recurrent intracranial germinoma is curable by HDC without re-irradiation, provided that the disease remains sensitive to salvage chemotherapy.
- ID情報
-
- DOI : 10.1002/pbc.27104
- ISSN : 1545-5009
- PubMed ID : 29693779